Amgen (NasdaqGS:AMGN) has recently garnered attention due to promising Phase 3 MINT trial results for UPLIZNA in treating ...

Baker Brothers' 13F portfolio value decreased from $9.65B to $9.36B. Check out the portfolio's top holdings and notable stake ...

Regeneron Pharmaceuticals, Inc. faces Eylea revenue decline but shows growth potential with Dupixent & Libtayo. Click for ...

Q4 2024 Earnings Call Transcript March 6, 2025 CytomX Therapeutics, Inc. beats earnings expectations. Reported EPS is $0.22, ...

Q4 2024 Earnings Call Transcript March 7, 2025 Operator: Good morning, and welcome to the Molecular Partners Fourth Quarter ...

Stocks to Consider. In this article, we are going to take a look at where Amgen Inc. (NASDAQ:AMGN) stands against other ...

In this article, we are going to take a look at where Amgen Inc. (NASDAQ ... which tracks over 1,000 hedge funds as of Q4 2024. Why are we interested in the stocks that hedge funds pile into?

As the global cancer crisis intensifies, the demand for breakthrough treatments is reaching new heights. Statista data ...

Annual net revenue increased 4% to $267.0 million in 2024, despite significant divestitures -- UDENYCA® net revenue increased 62% year-over-year -- LOQTORZI® net revenue increased 29% quarter-over-qua ...

The diabetes and weight loss drug market is heating up in 2025, with significant growth signs everywhere. According to a recent study from Research and Markets, industry growth is running at an ...

Investment analysts at William Blair issued their Q4 2026 earnings per share estimates for Amgen in a research report issued ...

RBC Capital analyst Gregory Renza maintained a Buy rating on aTyr Pharma (ATYR – Research Report) yesterday and set a price target of $16.00.